Cannabinoid receptor activation can inhibit tumor growth, trigger cancer cell death, and suppress blood vessel formation in preclinical studies, but clinical translation faces major challenges.
Researchers and patients interested in the potential of cannabinoid-based cancer therapies.
Three anti-cancer mechanisms: growth inhibition, cell death, anti-angiogenesis
What the researchers found
This review summarizes how the endocannabinoid system influences cancer through CB1 and CB2 receptor activation. Preclinical studies show cannabinoids can inhibit cell proliferation, induce apoptosis (programmed cell death), and suppress angiogenesis (new blood vessel formation). However, tumor heterogeneity, variable patient responses, and cannabinoid pharmacokinetic challenges remain significant barriers to clinical application.
Why it matters
Cancer treatment is in constant need of new approaches. The endocannabinoid system's ability to influence multiple cancer-relevant processes (growth, death, blood supply) makes it a compelling therapeutic target, even though clinical evidence remains limited.
The numbers in context
Two primary cannabinoid receptors (CB1, CB2) involved. Three main anti-cancer mechanisms: anti-proliferative, pro-apoptotic, anti-angiogenic. Clinical translation described as 'in its early stages.'
How the study worked
Mini-review of preclinical and early clinical literature on the endocannabinoid system's role in cancer biology, focusing on key mechanisms of cannabinoid-cancer interaction.
What this study cannot tell us
Mini-review, not systematic. Primarily preclinical evidence. Cancer types and models vary widely across studies. Pharmacokinetic challenges not fully addressed. Risk of publication bias toward positive preclinical results.
How to read the evidence
Moderate: synthesizes substantial preclinical evidence but clinical data remains very limited.
When this study was published
Published in 2025.
The bigger picture
While preclinical results are encouraging, the gap between lab findings and clinical reality remains wide. Tumor heterogeneity means cannabinoids may work against some cancer types but not others, and optimizing delivery to achieve therapeutic concentrations without psychoactive effects is an ongoing challenge.
Questions still open
- Which cancer types are most responsive to cannabinoid therapy?
- Can cannabinoids be combined with standard treatments to improve outcomes?
- How can the pharmacokinetic challenges of cannabinoids be overcome for cancer treatment?
Common questions
Can cannabinoids fight cancer?
Is the endocannabinoid system involved in cancer?
Read the original research
The endocannabinoid system in cancer biology: a mini-review of mechanisms and therapeutic potential.
Oncology reviews, 19, 1573797
Citation
Salum, Kaio Cezar Rodrigues; Miranda, Gabriel Brendo Alves; Dias, Alessandra Lima; Carneiro, João Regis Ivar; Bozza, Patrícia Torres; da Fonseca, Ana Carolina Proença; Silva, Tamara. (2025). The endocannabinoid system in cancer biology: a mini-review of mechanisms and therapeutic potential.. Oncology reviews, 19, 1573797. https://doi.org/10.3389/or.2025.1573797
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk